The pathophysiological mechanisms of psychiatric disease are very complex and multiple etiological processes are involved. The transcriptional level study may help to validate potential targets. RNA sequencing (RNA-Seq) has become a powerful tool for genetic research, which can be used for transcriptome analysis to understand the genetic mechanism of the psychiatric disease. Creative Biolabs provides target RNA expression analysis services to validate and qualify possible targets in psychiatric disorders drug development.
Introduction of RNA-Seq
RNA-Seq provides an unbiased way to investigate gene expression, and it has been widely used to research human complex disorders, including cancers as well as neurodegenerative and psychiatric diseases. Compared with other high-throughput RNA detection technologies, RNA-Seq has several advantages:
-
It needs a small amount of RNA as inputs and does not require probes based on the existing genomic sequence;
-
RNA-Seq has low background noise and can measure the transcripts in a single base level.
RNA-Seq can be used to sequence the brain transcriptome of human and animal models, which provided information about the transcriptional profiles in pathological states of psychiatric disorders.
RNA-Seq in Psychiatric Disorders
In the past few years, based on gene and expression studies, the number of reports proving that RNA molecules such as microRNA (miRNA) are involved in schizophrenia and bipolar disorder, as well as other psychiatric disorders including addiction, has steadily increased. For example, studies have shown that the best genetic signal associated with schizophrenia (SCZ) is a polymorphism in the primary transcript of hsa-miR-137. Further research combined genetic data from genome-wide association study (GWAS) and brain imaging results, and found that miR-137 are significantly rich in schizophrenia samples. Therefore, we can obtain information about the effectiveness of drug candidates through RNA-Seq analysis of the gene target.
Services in Creative Biolabs
Potential drug targets can be proteins, protein complexes, or RNA molecules, and we integrate evidence that they affect disease through genes that encode them. Through the detection of endogenous miRNA or mRNA expression, we can indirectly obtain the related changes after the target drug acts on the disease individual, and provide evidence correlation of target-disease association.
At present, Creative Biolabs uses RNA-Seq to identify the shared expression change patterns and investigate the etiological mechanisms for these common psychiatric disorders, which provides an unprecedented opportunity to discover the potential target for the development of the psychotropic drug. If you are interested in our services, please contact us. We will get back to you shortly with a solution made specifically for your request!
For Research Use Only.
